About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Boston | 17,836 Studies Near You | Clareo Health

Clinical Trials LocationsBoston

Clinical Trials in Boston

Discover 17,836 clinical trials near Boston, Massachusetts. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2581-2600 of 17,836 trials

COMPLETED< 1 mile

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

NCT04259125

The purpose of this study evaluate the relationship between inflammation and epilepsy in neonates with seizures after birth.

Neonatal SeizureEpilepsySeizures+1 more

University of California, San Francisco72 participantsStarted Dec 2018

Oakland, California, United States • San Francisco, California, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 3< 1 mile

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

NCT03505099

To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2

Spinal Muscular Atrophy

Novartis Gene Therapies30 participantsStarted Apr 2018

Los Angeles, California, United States • Aurora, Colorado, United States • Orlando, Florida, United States +13 more locations

Find Trials by Condition in Boston

Breast Cancerin Boston Lung Cancerin Boston Prostate Cancerin Boston Colorectal Cancerin Boston Melanomain Boston Leukemiain Boston Lymphomain Boston Pancreatic Cancerin Boston Ovarian Cancerin Boston Brain Cancerin Boston Diabetesin Boston

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 1< 1 mile

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

NCT02779751

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

Non Small Cell Lung CancerBreast Cancer

Eli Lilly and Company100 participantsStarted Nov 2016

Springdale, Arkansas, United States • San Francisco, California, United States • Aurora, Colorado, United States +21 more locations

Active Not RecruitingPhase 2< 1 mile

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

NCT04633889

Multiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind, placebo-controlled trial whether prophylactic administration of deferoxamine decreases the incidence of AKI following cardiac surgery.

Acute Kidney Injury

Brigham and Women's Hospital320 participantsStarted Apr 2021

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

Active Not RecruitingNA< 1 mile

Feasibility of the Comfort Measures Only Time Out (CMOT)

NCT05861323

Nearly 25% of Americans die in intensive care units (ICUs). Most deaths in ICUs are expected and involve the removal of ventilator support, or palliative withdrawal of mechanical ventilation (WMV). Prior work by the Principal Investigator (PI) found that patient suffering can be common; with 30-59% of patients going through this process experiencing distress. Thus, experts and national organizations have called for evidence to inform guidelines for WMV. This research study will 1) develop and refine a Comfort Measures Only Time out (CMOT) intervention consisting of a structured time out with check-list protocol for the ICU team (nurse, physician, respiratory therapist) to improve the process of WMV. and 2) Pilot test the CMOT intervention in 4 ICUs (2 medical/2 surgical) among 40 WMV patients.

End of LifeRespiratory FailureVentilatory Failure+2 more

Beth Israel Deaconess Medical Center184 participantsStarted Oct 2023

Boston, Massachusetts, United States

Active Not RecruitingPhase 2/3< 1 mile

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

Stage II Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8

Alliance for Clinical Trials in Oncology220 participantsStarted Jun 2020

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +790 more locations

RECRUITINGEARLY Phase 1< 1 mile

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782

This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice

Salivary Gland CancerAdenoid Cystic Carcinoma of the Salivary GlandSquamous Cell Carcinoma of Head and Neck+1 more

Brigham and Women's Hospital30 participantsStarted Nov 2023

Boston, Massachusetts, United States • Boston, Massachusetts, United States

Not Yet Recruiting< 1 mile

Postoperative Assessment of Platelet-Rich Plasma and Platelet-Rich Fibrin in Temporomandibular Joint Surgery

NCT07359131

The goal of this observational study is to evaluate postoperative outcomes following temporomandibular joint (TMJ) surgery and to compare the effectiveness of intraoperative platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) injections in patients with temporomandibular joint disorders. The study includes adult patients who underwent TMJ surgery and received either PRP or PRF intraoperatively. The main questions this study aims to answer are: Whether intraoperative PRP or PRF injection is associated with differences in postoperative pain intensity and recovery. Whether PRP and PRF differ in their effects on postoperative jaw function, including maximum mouth opening and joint symptoms. If there is a comparison group: Researchers will compare patients who received intraoperative PRP with those who received intraoperative PRF to assess differences in postoperative pain, functional outcomes, and joint-related symptoms. Participants will: Have their existing medical records reviewed retrospectively. Provide postoperative outcome data derived from routine clinical follow-up, with no prospective recruitment or intervention.

Temporomandibular Joint Disorders

Jingping Wang, MD, Ph.D.700 participantsStarted Jan 2026

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Optimizing the Safety of Inter-Hospital Transfer

NCT05876429

This proposal aims to design, implement and rigorously evaluate a standardized accept note in a population of patients that have high frequency of IHT, including patients transferred to the general medical (GMS), cardiology and oncology services at a large tertiary care hospital. This study will improve scientific knowledge by quantifying the patient safety impact of an intervention to improve communication of essential clinical information during IHT. If shown effective, the results of this study can be used to improve clinical practice by establishing evidence-based communication guidelines for broad dissemination. We will also establish technical feasibility by successfully implementing this tool within our EHR (Epic, Verona, WI), allowing for feasible adoption and dissemination to other institutions with similar EHR capabilities. Lastly, we will address malpractice risk by investigating a strategic intervention aimed at reducing known contributors to patient harm during IHT, a high-risk transition in care that involves transfer of high-acuity patients between providers, settings and systems of care.

Inpatient Facililty Diagnoses

Brigham and Women's Hospital1,658 participantsStarted Aug 2020

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)

NCT05114733

The purpose of this study is to test the efficacy of InVEST (Individualized Vocational and Educational Support and Training) for CHR-P (clinical high risk for psychosis) to address specific role functioning difficulties associated with the CHR-P phase. Our specific goals are: 1. Part 1: Preliminary open trial of InVEST (n = 8) to collect preliminary feasibility and acceptability data by providing the intervention, administering assessments, and collecting focus group and self-report feedback from open trial participants. The open trial phase will help to refine recruitment approaches and to modify the treatment manual as needed. 2. Part 2: Preliminary randomized controlled trial of InVEST vs. Delayed InVEST (DI) to explore preliminary evidence of efficacy of InVEST vs. DI (n = 30). The investigators hope to gain understanding of the feasibility of InVEST and the study's assessment procedures, and to gain a preliminary understanding of the intervention's efficacy for functioning difficulties experienced by young people at CHR-P.

Clinical High Risk for Psychosis

Beth Israel Deaconess Medical Center26 participantsStarted Feb 2022

Boston, Massachusetts, United States

Enrolling By InvitationNA< 1 mile

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

NCT05443321

Sub-optimal transfer of clinical information during inter-hospital transfer (IHT, the transfer of patients between acute care hospitals) is common and can lead to patient harm. To address this problem, the investigators will use key stakeholder input to refine and implement an interoperable health information exchange platform that integrates with the electronic health record and improves the reliability of and access to necessary clinical information in three use cases involving transfer of patients between sending and receiving hospitals with varying levels of affiliation and health record integration. The investigators will assess the effect of this intervention on frequency of medical errors, evaluate the use and usability of this platform from the perspective of those that interact with it, and use these results to develop a dissemination plan to spread implementation and use of this platform across other similar institutions.

InfectionsHeart FailureCOPD Exacerbation+13 more

Brigham and Women's Hospital1,006 participantsStarted Nov 2022

Boston, Massachusetts, United States

COMPLETEDPhase 1/2< 1 mile

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

NCT00626860

This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.

Metastatic Melanoma

Beth Israel Deaconess Medical Center20 participantsStarted Jul 2000

Boston, Massachusetts, United States

COMPLETEDPhase 1/2< 1 mile

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

NCT00625755

This study will look how using taken from your tumors and mixed with special immune stimulating cells from another person's blood in given back to you in a series "fusion cell" injections, will effect your body. The primary goal of the study is to see if giving the experimental fusion cell injections is safe. We will also be looking to see what effect the experimental treatment as on your immune system and whether it has an effect on your cancer.

Renal Cell Carcinoma

Beth Israel Deaconess Medical Center40 participantsStarted Dec 2002

Boston, Massachusetts, United States

RECRUITING2.6 miles

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

NCT05561647

The study is about learning and documenting how well participants and physicians understand how to use GATTEX and about potential risks by using a survey (called Knowledge Assessment Survey). This survey, which is conducted every two years, is part of the Gattex Risk Evaluation and Mitigation Strategy (REMS). REMS is a safety program required by the US health authority (FDA) for certain medicines that have serious risks. REMS intends to help reduce these risks while still allowing treatment. The goal is to make sure these medicines are used in the safest way possible. The main aim of this survey is to find out how well participants and physicians understand the checkups and tests (so called monitoring) participants should have while taking GATTEX, and the possible risks or of using GATTEX to treat Short Bowel Syndrome. The knowledge assessment survey will be done via internet, telephone, or paper and both physicians and participants will be able to choose the method that is preferred. No study medicines will be provided to participants in this study.

Short Bowel Syndrome (SBS)

Takeda600 participantsStarted Aug 2013

Cambridge, Massachusetts, United States

Active Not RecruitingPhase 1251 miles

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

NCT05081180

This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with Lenvatinib and determine the recommended Avelumab and Lenvatinib dose for expansion. Dose Expansion Part 2 will assess the efficacy of Avelumab in combination with Lenvatinib by Progression-free Survival in participants with pre-defined primary central nervous system (CNS) tumors.

Central Nervous System Tumors

EMD Serono Research & Development Institute, Inc.17 participantsStarted Dec 2021

Montreal, Canada • Toronto, Canada • Angers, France +6 more locations

COMPLETEDPhase 3313 miles

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Hereditary Angioedema (HAE)

CSL Behring22 participantsStarted May 2023

Litchfield Park, Arizona, United States • Scottsdale, Arizona, United States • Orange, California, United States +10 more locations

Active Not RecruitingPhase 1550 miles

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

NCT06150183

The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.

Advanced Malignant Solid Tumor

BioNTech SE41 participantsStarted Nov 2023

Grand Rapids, Michigan, United States • Huntersville, North Carolina, United States • Cleveland, Ohio, United States +11 more locations

RECRUITINGPhase 1/2618 miles

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839

The study consists of three parts: * Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). * Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different dose ratios of belantamab mafodotin in combination with Unconjugated belantamab antibody (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). * Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the unconjugated belantamab antibody, either alone or in combination with belantamab mafodotin alongside the standard of care (SoC) pomalidomide-dexamethasone backbone. The study will focus on patients with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.

Multiple Myeloma

GlaxoSmithKline153 participantsStarted Jun 2023

Grand Rapids, Michigan, United States • Chapel Hill, North Carolina, United States • Chattanooga, Tennessee, United States +24 more locations

COMPLETEDPhase 1850 miles

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

NCT05174221

This study will have two parts. The main aims are to: * check the side effects from mezagitamab. * check for long-term side effects from mezagitamab. Before starting the study, participants will be asked to provide a 24-hour urine sample. A few weeks later, if enrolled they will begin receiving a subcutaneous injection (under the skin) of mezagitamab once a week for 8 weeks then once every 2 weeks for 16 weeks. When treatment has ended, there will be a 24-week follow-up period. Participants who receive benefit from the treatment may continue in the second part of the study where they will be monitored for up to 96 weeks and possibly retreated for another 24 weeks.

Kidney DiseaseGlomerulonephritis

Takeda17 participantsStarted Nov 2022

Northridge, California, United States • Nampa, Idaho, United States • Evanston, Illinois, United States +23 more locations

COMPLETEDPhase 2898 miles

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

NCT04564547

This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency virus type 1 (HIV-1) who have been virologically suppressed for ≥6 months on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once-daily.

HIV-1 Infection

Merck Sharp & Dohme LLC161 participantsStarted Mar 2021

Phoenix, Arizona, United States • Los Angeles, California, United States • Ft. Pierce, Florida, United States +20 more locations

PreviousPage 130 of 892Next

Heart Diseasein Boston